These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

489 related articles for article (PubMed ID: 26160192)

  • 1. A mutation spectrum that includes GNAS, KRAS and TP53 may be shared by mucinous neoplasms of the appendix.
    Hara K; Saito T; Hayashi T; Yimit A; Takahashi M; Mitani K; Takahashi M; Yao T
    Pathol Res Pract; 2015 Sep; 211(9):657-64. PubMed ID: 26160192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular and clinicopathological features of appendiceal mucinous neoplasms.
    Yanai Y; Saito T; Hayashi T; Akazawa Y; Yatagai N; Tsuyama S; Tomita S; Hirai S; Ogura K; Matsumoto T; Wada R; Yao T
    Virchows Arch; 2021 Mar; 478(3):413-426. PubMed ID: 32821969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heterogeneous mutational profile and prognosis conferred by TP53 mutations in appendiceal mucinous neoplasms.
    Zhu X; Salhab M; Tomaszewicz K; Meng X; Mathew C; Bathini V; Switzer B; Walter O; Cosar EF; Wang X; Lambert LA; Hutchinson LM
    Hum Pathol; 2019 Mar; 85():260-269. PubMed ID: 30458197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutation profile of high-grade appendiceal mucinous neoplasm.
    Liao X; Vavinskaya V; Sun K; Hao Y; Li X; Valasek M; Xu R; Polydorides AD; Houldsworth J; Harpaz N
    Histopathology; 2020 Feb; 76(3):461-469. PubMed ID: 31491041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GNAS is frequently mutated in both low-grade and high-grade disseminated appendiceal mucinous neoplasms but does not affect survival.
    Singhi AD; Davison JM; Choudry HA; Pingpank JF; Ahrendt SA; Holtzman MP; Zureikat AH; Zeh HJ; Ramalingam L; Mantha G; Nikiforova M; Bartlett DL; Pai RK
    Hum Pathol; 2014 Aug; 45(8):1737-43. PubMed ID: 24925222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. KRAS and GNAS Co-Mutation in Metastatic Low-Grade Appendiceal Mucinous Neoplasm (LAMN) to the Ovaries: A Practical Role for Next-Generation Sequencing.
    Matson DR; Xu J; Huffman L; Barroilhet L; Accola M; Rehrauer WM; Weisman P
    Am J Case Rep; 2017 May; 18():558-562. PubMed ID: 28526814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frequent GNAS mutations in low-grade appendiceal mucinous neoplasms.
    Nishikawa G; Sekine S; Ogawa R; Matsubara A; Mori T; Taniguchi H; Kushima R; Hiraoka N; Tsuta K; Tsuda H; Kanai Y
    Br J Cancer; 2013 Mar; 108(4):951-8. PubMed ID: 23403822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lobular endocervical glandular hyperplasia is a neoplastic entity with frequent activating GNAS mutations.
    Matsubara A; Sekine S; Ogawa R; Yoshida M; Kasamatsu T; Tsuda H; Kanai Y
    Am J Surg Pathol; 2014 Mar; 38(3):370-6. PubMed ID: 24145653
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular biomarkers for progression of intraductal papillary mucinous neoplasm of the pancreas.
    Kuboki Y; Shimizu K; Hatori T; Yamamoto M; Shibata N; Shiratori K; Furukawa T
    Pancreas; 2015 Mar; 44(2):227-35. PubMed ID: 25423558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular and Genetic Markers in Appendiceal Mucinous Tumors: A Systematic Review.
    Stein A; Strong E; Clark Gamblin T; Clarke C; Tsai S; Thomas J; George B; Mogal H
    Ann Surg Oncol; 2020 Jan; 27(1):85-97. PubMed ID: 31583543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Impact of KRAS and GNAS Analysis Added to CEA and Cytology in Pancreatic Cystic Fluid Obtained by EUS-FNA.
    Faias S; Duarte M; Albuquerque C; da Silva JP; Fonseca R; Roque R; Dias Pereira A; Chaves P; Cravo M
    Dig Dis Sci; 2018 Sep; 63(9):2351-2361. PubMed ID: 29796909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Value of adding GNAS testing to pancreatic cyst fluid KRAS and carcinoembryonic antigen analysis for the diagnosis of intraductal papillary mucinous neoplasms.
    Kadayifci A; Atar M; Wang JL; Forcione DG; Casey BW; Pitman MB; Brugge WR
    Dig Endosc; 2017 Jan; 29(1):111-117. PubMed ID: 27514845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GNAS and KRAS Mutations Define Separate Progression Pathways in Intraductal Papillary Mucinous Neoplasm-Associated Carcinoma.
    Tan MC; Basturk O; Brannon AR; Bhanot U; Scott SN; Bouvier N; LaFemina J; Jarnagin WR; Berger MF; Klimstra D; Allen PJ
    J Am Coll Surg; 2015 May; 220(5):845-854.e1. PubMed ID: 25840541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GNAS mutation is a frequent event in pancreatic intraductal papillary mucinous neoplasms and associated adenocarcinomas.
    Hosoda W; Sasaki E; Murakami Y; Yamao K; Shimizu Y; Yatabe Y
    Virchows Arch; 2015 Jun; 466(6):665-74. PubMed ID: 25796395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The discrete nature and distinguishing molecular features of pancreatic intraductal tubulopapillary neoplasms and intraductal papillary mucinous neoplasms of the gastric type, pyloric gland variant.
    Yamaguchi H; Kuboki Y; Hatori T; Yamamoto M; Shimizu K; Shiratori K; Shibata N; Shimizu M; Furukawa T
    J Pathol; 2013 Nov; 231(3):335-41. PubMed ID: 23893889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular Profiling of Appendiceal Adenocarcinoma and Comparison with Right-sided and Left-sided Colorectal Cancer.
    Tokunaga R; Xiu J; Johnston C; Goldberg RM; Philip PA; Seeber A; Naseem M; Lo JH; Arai H; Battaglin F; Puccini A; Berger MD; Soni S; Zhang W; Hwang JJ; Shields AF; Marshall JL; Baba H; Korn WM; Lenz HJ
    Clin Cancer Res; 2019 May; 25(10):3096-3103. PubMed ID: 30692096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intraductal papillary mucinous neoplasms of the pancreas with distinct pancreatic ductal adenocarcinomas are frequently of gastric subtype.
    Ideno N; Ohtsuka T; Kono H; Fujiwara K; Oda Y; Aishima S; Ito T; Ishigami K; Tokunaga S; Ohuchida K; Takahata S; Nakamura M; Mizumoto K; Tanaka M
    Ann Surg; 2013 Jul; 258(1):141-51. PubMed ID: 23532108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discrimination of low- and high-grade appendiceal mucinous neoplasms by targeted sequencing of cancer-related variants.
    LaFramboise WA; Pai RK; Petrosko P; Belsky MA; Dhir A; Howard PG; Becich MJ; Holtzman MP; Ahrendt SA; Pingpank JF; Zeh HJ; Dhir R; Bartlett DL; Choudry HA
    Mod Pathol; 2019 Jul; 32(8):1197-1209. PubMed ID: 30962504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular profiling of appendiceal serrated lesions, polyps and mucinous neoplasms: a single-centre experience.
    Munari G; Businello G; Mattiolo P; Pennelli G; Sbaraglia M; Borga C; Pucciarelli S; Spolverato G; Mescoli C; Galuppini F; Sommariva A; Bellan E; Lonardi S; Loupakis F; Luchini C; Dei Tos AP; Fassan M
    J Cancer Res Clin Oncol; 2021 Jul; 147(7):1897-1904. PubMed ID: 33712927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.
    Rechsteiner M; Zimmermann AK; Wild PJ; Caduff R; von Teichman A; Fink D; Moch H; Noske A
    Exp Mol Pathol; 2013 Oct; 95(2):235-41. PubMed ID: 23965232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.